|
AU2009307677C1
(en)
|
2008-10-20 |
2022-09-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
EP3444348A1
(en)
|
2011-06-21 |
2019-02-20 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
|
IL303831A
(en)
*
|
2011-11-18 |
2023-08-01 |
Alnylam Pharmaceuticals Inc |
Adapted RNAI factors
|
|
CN112007045B
(zh)
|
2012-07-13 |
2026-01-06 |
波涛生命科学有限公司 |
手性控制
|
|
KR102463973B1
(ko)
|
2013-05-22 |
2022-11-07 |
알닐람 파마슈티칼스 인코포레이티드 |
ＳＥＲＰＩＮＡ1 ｉＲＮＡ 조성물 및 이의 사용 방법
|
|
IL316808A
(en)
*
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
WO2016161388A1
(en)
|
2015-04-03 |
2016-10-06 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
|
KR20250005546A
(ko)
|
2015-04-13 |
2025-01-09 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오포이에틴-유사 3(angptl3) irna 조성물 및 이의 이용 방법
|
|
JP6896703B2
(ja)
|
2015-07-31 |
2021-06-30 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ＴＴＲ関連疾患を治療または予防するためのトランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物およびその使用方法
|
|
WO2017030973A1
(en)
|
2015-08-14 |
2017-02-23 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
US10478503B2
(en)
|
2016-01-31 |
2019-11-19 |
University Of Massachusetts |
Branched oligonucleotides
|
|
JP2019511562A
(ja)
*
|
2016-02-01 |
2019-04-25 |
アラーキス セラピューティクス， インコーポレイテッド |
Ｒｎａ媒介疾患を処置する化合物および方法
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
|
US10858656B2
(en)
|
2016-04-01 |
2020-12-08 |
Avidity Biosciences, Inc. |
KRAS nucleic acids and uses thereof
|
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
|
CA3023764A1
(en)
|
2016-06-06 |
2017-12-14 |
Arrowhead Pharmaceuticals, Inc. |
5'-cyclo-phosphonate modified nucleotides
|
|
US11753638B2
(en)
|
2016-08-12 |
2023-09-12 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
WO2018035380A1
(en)
*
|
2016-08-17 |
2018-02-22 |
Solstice Biologics, Ltd. |
Polynucleotide constructs
|
|
WO2018085752A2
(en)
*
|
2016-11-07 |
2018-05-11 |
nanoSUR LLC |
Post-transcriptionally chemically modified double strand rnas
|
|
US11447519B2
(en)
|
2016-11-10 |
2022-09-20 |
San Diego State University Research Foundation |
Compounds for fluorescence sensing of duplex formation
|
|
KR102645243B1
(ko)
|
2016-11-23 |
2024-03-11 |
알닐람 파마슈티칼스 인코포레이티드 |
표적외 효과가 감소된 변형 rna 작용제
|
|
TW202313978A
(zh)
*
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
BR112019012154A2
(pt)
|
2016-12-14 |
2019-11-12 |
Janssen Biotech, Inc. |
domínios do tipo iii da fibronectina de ligação a cd8a
|
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
AU2017376950B2
(en)
*
|
2016-12-16 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
|
|
EP3550022A1
(en)
*
|
2018-04-05 |
2019-10-09 |
Silence Therapeutics GmbH |
Products and compositions
|
|
RS63836B1
(sr)
|
2017-04-05 |
2023-01-31 |
Silence Therapeutics Gmbh |
Proizvodi i sastavi
|
|
JP7247167B2
(ja)
*
|
2017-04-05 |
2023-03-28 |
サイレンス・セラピューティクス・ゲーエムベーハー |
産物及び組成物
|
|
CA3064590A1
(en)
|
2017-06-23 |
2018-12-27 |
University Of Massachusetts |
Two-tailed self-delivering sirna and related methods
|
|
WO2019006455A1
(en)
|
2017-06-30 |
2019-01-03 |
Solstice Biologics, Ltd. |
AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
|
|
PE20201287A1
(es)
|
2017-09-14 |
2020-11-24 |
Arrowhead Pharmaceuticals Inc |
Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
|
|
KR20200089656A
(ko)
|
2017-09-19 |
2020-07-27 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
|
|
US11110180B2
(en)
*
|
2017-10-04 |
2021-09-07 |
Avidity Biosciences Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
MX2020004898A
(es)
*
|
2017-11-13 |
2020-10-05 |
Silence Therapeutics Gmbh |
Ácidos nucleicos para inhibir la expresión de un gen diana que comprende enlaces fosforoditioato.
|
|
US11807623B2
(en)
|
2017-11-30 |
2023-11-07 |
Arrakis Therapeutics, Inc. |
Nucleic acid-binding photoprobes and uses thereof
|
|
WO2019105435A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
JP7261494B2
(ja)
|
2017-12-01 |
2023-04-20 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
CN110945131B
(zh)
*
|
2017-12-01 |
2024-05-28 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN110997919B
(zh)
|
2017-12-01 |
2024-04-02 |
苏州瑞博生物技术股份有限公司 |
双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
|
|
CN111050807B
(zh)
*
|
2017-12-01 |
2024-05-28 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
US11660347B2
(en)
|
2017-12-01 |
2023-05-30 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
|
|
CN118236391A
(zh)
*
|
2017-12-01 |
2024-06-25 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN118638788A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
EP3728281A1
(en)
*
|
2017-12-21 |
2020-10-28 |
Alnylam Pharmaceuticals Inc. |
Chirally-enriched double-stranded rna agents
|
|
WO2019127004A1
(zh)
*
|
2017-12-26 |
2019-07-04 |
广州市锐博生物科技有限公司 |
修饰的寡核苷酸和可用于合成修饰的寡核苷酸的化合物
|
|
CN110959011B
(zh)
|
2017-12-29 |
2023-03-28 |
苏州瑞博生物技术股份有限公司 |
缀合物及其制备方法和用途
|
|
CN112055597A
(zh)
*
|
2018-03-02 |
2020-12-08 |
迪克纳制药公司 |
用于治疗胆管缺乏相关病况的方法和组合物
|
|
KR102857148B1
(ko)
*
|
2018-04-05 |
2025-09-11 |
사일런스 테라퓨틱스 게엠베하 |
안티센스 가닥의 5' 단부에 비닐포스포네이트를 갖는 siRNA
|
|
US20210155926A1
(en)
*
|
2018-04-05 |
2021-05-27 |
Silence Therapeutics Gmbh |
siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS
|
|
EP3790970A1
(en)
|
2018-05-07 |
2021-03-17 |
Alnylam Pharmaceuticals Inc. |
Extrahepatic delivery
|
|
WO2019217397A2
(en)
*
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for improving strand biased
|
|
US12247203B2
(en)
|
2018-05-16 |
2025-03-11 |
Alnylam Pharmaceuticals, Inc. |
Modified RNA agents with reduced off-target effect
|
|
EP3842534A4
(en)
*
|
2018-08-21 |
2022-07-06 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE
|
|
JP7627042B2
(ja)
*
|
2018-08-23 |
2025-02-05 |
ユニバーシティー オブ マサチューセッツ |
Ｏ－メチルリッチ完全安定化オリゴヌクレオチド
|
|
JP7470107B2
(ja)
*
|
2018-09-28 |
2024-04-17 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
トランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物及びＴＴＲ関連眼疾患を治療又は予防するためのその使用方法
|
|
EP3862024A4
(en)
*
|
2018-09-30 |
2022-08-17 |
Suzhou Ribo Life Science Co., Ltd. |
SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
|
|
WO2020097044A1
(en)
*
|
2018-11-09 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Modified double stranded oligonucleotides
|
|
CN119061010A
(zh)
*
|
2018-12-10 |
2024-12-03 |
美国安进公司 |
经化学修饰的RNAi构建体及其用途
|
|
WO2020123327A1
(en)
|
2018-12-10 |
2020-06-18 |
Amgen Inc. |
Mutated piggybac transposase
|
|
CR20210393A
(es)
*
|
2018-12-19 |
2021-10-27 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTE DE ARNi DE PROTEÍNA PRECURSORA DE AMILOIDE (APP) Y MÉTODO DE USO DE LAS MISMAS
|
|
LT4285929T
(lt)
|
2018-12-20 |
2026-01-12 |
Humabs Biomed Sa |
Kompleksinė hbv terapija
|
|
CN112423794A
(zh)
*
|
2018-12-28 |
2021-02-26 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN111378655B
(zh)
*
|
2018-12-28 |
2024-03-19 |
苏州瑞博生物技术股份有限公司 |
抑制CTGF基因表达的siRNA、含有该siRNA的药物组合物及其用途
|
|
CN111378657B
(zh)
*
|
2018-12-28 |
2024-03-15 |
苏州瑞博生物技术股份有限公司 |
抑制COL1A1基因表达的siRNA、含有该siRNA的药物组合物及其用途
|
|
CN112423795A
(zh)
*
|
2018-12-28 |
2021-02-26 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN111378658B
(zh)
*
|
2018-12-28 |
2024-03-15 |
苏州瑞博生物技术股份有限公司 |
抑制TIMP-1基因表达的siRNA、含有该siRNA的药物组合物及其用途
|
|
CN111378659B
(zh)
*
|
2018-12-29 |
2024-01-30 |
苏州瑞博生物技术股份有限公司 |
抑制stat3基因表达的核酸、含有该核酸的药物组合物及其用途
|
|
WO2020147847A1
(zh)
*
|
2019-01-18 |
2020-07-23 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2020150636A1
(en)
|
2019-01-18 |
2020-07-23 |
University Of Massachusetts |
Dynamic pharmacokinetic-modifying anchors
|
|
EP3946374A4
(en)
*
|
2019-03-29 |
2023-07-19 |
University of Massachusetts |
OLIGONUCLEOTIDE-BASED MODULATION OF C9ORF72
|
|
WO2020227395A2
(en)
|
2019-05-06 |
2020-11-12 |
University Of Massachusetts |
Anti-c9orf72 oligonucleotides and related methods
|
|
TWI902693B
(zh)
*
|
2019-05-13 |
2025-11-01 |
美商維爾生物科技公司 |
用於治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物及方法
|
|
US20220211743A1
(en)
*
|
2019-05-17 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
|
AU2020280439B2
(en)
|
2019-05-22 |
2025-08-14 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
JP7663951B2
(ja)
|
2019-05-22 |
2025-04-17 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、薬物組成物及び複合体ならびに調製方法と使用
|
|
CN113811613B
(zh)
|
2019-05-22 |
2024-04-05 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN111973619B
(zh)
*
|
2019-05-23 |
2024-01-30 |
苏州瑞博生物技术股份有限公司 |
核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
|
|
WO2020238766A1
(zh)
|
2019-05-24 |
2020-12-03 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN118217305A
(zh)
*
|
2019-05-24 |
2024-06-21 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
US20220315929A1
(en)
*
|
2019-05-24 |
2022-10-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof
|
|
AR119061A1
(es)
*
|
2019-05-30 |
2021-11-17 |
Amgen Inc |
CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE SCAP Y MÉTODOS DE USO DE LAS MISMAS
|
|
CN112007040B
(zh)
*
|
2019-05-31 |
2024-01-30 |
苏州瑞博生物技术股份有限公司 |
用于治疗乙型病毒性肝炎的联合用药物
|
|
US12006499B2
(en)
|
2019-06-06 |
2024-06-11 |
Avidity Biosciences, Inc. |
Una amidites and uses thereof
|
|
CA3142283A1
(en)
|
2019-06-06 |
2020-12-10 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
CA3138627A1
(en)
*
|
2019-06-21 |
2020-12-24 |
Alexander V. KEL'IN |
Structurally defined sirna-dual variable domain immunoglobulin conjugates
|
|
CA3149835A1
(en)
|
2019-08-09 |
2021-02-18 |
University Of Massachusetts |
Chemically modified oligonucleotides targeting snps
|
|
KR20220062517A
(ko)
|
2019-08-15 |
2022-05-17 |
아이오니스 파마수티컬즈, 인코포레이티드 |
결합 변형된 올리고머 화합물 및 이의 용도
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
WO2021076546A1
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Cd71 binding fibronectin type iii domains
|
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
US12491255B2
(en)
|
2019-10-14 |
2025-12-09 |
Aro Biotherapeutics Company |
EPCAM binding fibronectin type III domains
|
|
AU2020378414A1
(en)
*
|
2019-11-06 |
2022-05-26 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
EP4055165A1
(en)
*
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
CN112876534B
(zh)
*
|
2019-11-29 |
2024-02-09 |
苏州瑞博生物技术股份有限公司 |
肝靶向化合物及缀合物
|
|
JP7802676B2
(ja)
*
|
2020-03-06 |
2026-01-20 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
トランスサイレチン（ｔｔｒ）の発現を阻害するための組成物および方法
|
|
WO2021188390A1
(en)
|
2020-03-19 |
2021-09-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
WO2021195469A1
(en)
|
2020-03-27 |
2021-09-30 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
|
MX2022012293A
(es)
*
|
2020-03-30 |
2022-10-27 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de acido ribonucleico de interferencia (arni) de la proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
|
|
CN115698288A
(zh)
*
|
2020-04-08 |
2023-02-03 |
北京瑞博开拓医药科技有限公司 |
核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
|
|
EP4157289A4
(en)
|
2020-05-26 |
2024-06-26 |
University Of Massachusetts |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
EP4165186A4
(en)
*
|
2020-06-16 |
2024-10-16 |
Alnylam Pharmaceuticals, Inc. |
ANAPLASTIC LYMPHOMA KINASE (ALK)-IRNA ACTIVE COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2022011214A1
(en)
|
2020-07-10 |
2022-01-13 |
Alnylam Pharmaceuticals, Inc. |
Circular sirnas
|
|
CA3190477A1
(en)
*
|
2020-07-30 |
2022-02-03 |
Adarx Pharmaceuticals, Inc. |
Adar dependent editing compositions and methods of use thereof
|
|
US12329828B2
(en)
|
2020-09-16 |
2025-06-17 |
San Diego State University (Sdsu) Foundation |
Pyrimidine nucleoside compounds for fluorescence imaging and spectroscopy
|
|
CN116333013B
(zh)
*
|
2020-09-30 |
2025-09-02 |
纳肽得(青岛)生物医药有限公司 |
一种靶向配体
|
|
CR20230308A
(es)
|
2020-12-11 |
2023-09-08 |
Civi Biopharma Inc |
Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
|
|
CN114685585B
(zh)
*
|
2020-12-31 |
2024-06-04 |
苏州瑞博生物技术股份有限公司 |
核苷酸序列、双链寡核苷酸、药物组合物与缀合物及制备方法和用途
|
|
EP4277636A4
(en)
*
|
2021-01-15 |
2025-11-26 |
Alnylam Pharmaceuticals Inc |
MODIFIED OLIGONUCLEOTIDES
|
|
EP4281085A4
(en)
*
|
2021-01-22 |
2025-12-24 |
Alnylam Pharmaceuticals Inc |
MODIFIED DOUBLE-STRANDED OLIGONUCLEOTIDES
|
|
EP4291654A2
(en)
|
2021-02-12 |
2023-12-20 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
AU2022231003A1
(en)
|
2021-03-04 |
2023-09-14 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
|
WO2022189861A1
(en)
|
2021-03-08 |
2022-09-15 |
Tollys |
Carbohydrate conjugates of tlr3 ligands and uses thereof
|
|
IL307239A
(en)
|
2021-03-29 |
2023-11-01 |
Alnylam Pharmaceuticals Inc |
Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
|
|
IL307582A
(en)
|
2021-04-14 |
2023-12-01 |
Aro Biotherapeutics Company |
CD71-binding domains of the fibronectin type
|
|
US12239710B2
(en)
|
2021-04-14 |
2025-03-04 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
AR126207A1
(es)
|
2021-06-23 |
2023-09-27 |
Univ Massachusetts |
Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogénicos
|
|
AU2022299514A1
(en)
*
|
2021-06-24 |
2024-01-18 |
Sirnaomics, Inc. |
Products and compositions
|
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
|
KR20240036041A
(ko)
|
2021-07-21 |
2024-03-19 |
알닐람 파마슈티칼스 인코포레이티드 |
대사 장애-연관 표적 유전자 iRNA 조성물 및 이의 사용 방법
|
|
TW202328445A
(zh)
|
2021-08-03 |
2023-07-16 |
美商艾拉倫製藥股份有限公司 |
甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其使用方法
|
|
MX2024003266A
(es)
|
2021-09-16 |
2024-04-03 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
|
|
MX2024003519A
(es)
|
2021-09-24 |
2024-04-01 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
|
|
IL311864A
(en)
|
2021-10-15 |
2024-06-01 |
Alnylam Pharmaceuticals Inc |
IRNA compositions for extrahepatic administration and methods of using them
|
|
EP4419536A4
(en)
*
|
2021-10-19 |
2026-04-15 |
Alnylam Pharmaceuticals Inc |
2'-DEOXY-2'-F-2'-C-METHYL NUCLEOTIDES
|
|
WO2023088227A1
(zh)
|
2021-11-16 |
2023-05-25 |
上海舶望制药有限公司 |
抑制血管紧张素原(agt)蛋白表达的组合物和方法
|
|
CN118339294A
(zh)
*
|
2021-12-16 |
2024-07-12 |
上海拓界生物医药科技有限公司 |
一种dsRNA、其制备方法及应用
|
|
US20250074933A1
(en)
*
|
2022-01-05 |
2025-03-06 |
Rona Bioscience, Limited |
Double-stranded rna having nucleotide analog
|
|
IL315546A
(en)
|
2022-03-16 |
2024-11-01 |
Empirico Inc |
GALNAC compositions to improve siRNA bioavailability
|
|
US20250188478A1
(en)
|
2022-03-16 |
2025-06-12 |
Daiichi Sankyo Company, Limited |
siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2
|
|
JPWO2023176863A1
(enExample)
|
2022-03-16 |
2023-09-21 |
|
|
|
US12258563B2
(en)
|
2022-03-28 |
2025-03-25 |
Empirico Inc. |
Modified oligonucleotides
|
|
AU2023356356A1
(en)
*
|
2022-10-07 |
2025-04-10 |
Alnylam Pharmaceuticals, Inc. |
Plasminogen (plg) irna compositions and methods of use thereof
|
|
EP4653532A3
(en)
|
2022-12-19 |
2026-04-29 |
Arnatar Therapeutics, Inc |
Advanced rna targeting (arnatar)
|
|
WO2024153166A1
(zh)
|
2023-01-20 |
2024-07-25 |
石药集团中奇制药技术（石家庄）有限公司 |
一种经修饰的核苷单体及双链核糖核酸
|
|
WO2024175586A2
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Inhibitors of synaptogyrin-3 expression
|
|
JP2026507051A
(ja)
|
2023-02-21 |
2026-02-27 |
ブイアイビー ブイゼットダブリュ |
シナプトギリン－３発現を調節するためのオリゴヌクレオチド
|
|
WO2024208249A1
(zh)
|
2023-04-06 |
2024-10-10 |
上海舶望制药有限公司 |
5'-膦酸酯修饰的核苷类似物及其制备的寡核苷酸
|
|
WO2024229377A1
(en)
*
|
2023-05-03 |
2024-11-07 |
Ionis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides and uses thereof
|
|
TW202508607A
(zh)
*
|
2023-05-19 |
2025-03-01 |
大陸商北京炫景瑞醫藥科技有限公司 |
雙股寡核苷酸及其共軛物和用途
|
|
WO2024259134A1
(en)
|
2023-06-13 |
2024-12-19 |
Arnatar Therapeutics, Inc |
Advanced rna targeting (arnatar) for angiotensinogen
|
|
WO2024263883A2
(en)
*
|
2023-06-22 |
2024-12-26 |
The University Of North Carolina At Chapel Hill |
5' antisense dna modifications to enhance rna interference activity
|
|
EP4735602A2
(en)
|
2023-06-27 |
2026-05-06 |
Atrium Therapeutics, Inc. |
Compositions and methods of using prkag2-targeting antibody-oligonucleotide conjugates abstract
|
|
CN121793987A
(zh)
|
2023-06-30 |
2026-04-03 |
艾维迪提生物科学公司 |
使用pln靶向性抗体-寡核苷酸缀合物的组合物和方法
|
|
CN118063533B
(zh)
*
|
2023-09-18 |
2024-08-27 |
广州必贝特医药股份有限公司 |
修饰的核苷酸化合物、其寡聚核苷酸及其应用
|
|
IL326940A
(en)
|
2023-09-21 |
2026-05-01 |
Alnylam Pharmaceuticals Inc |
Activin A Receptor Type 1C (ACVR1C) IRNA Compositions and Methods of Using Them
|
|
CN117534717A
(zh)
*
|
2024-01-09 |
2024-02-09 |
凯莱英生命科学技术(天津)有限公司 |
5′-(e)-乙烯基磷酸酯的合成方法
|
|
EP4671372A3
(en)
|
2024-01-29 |
2026-03-11 |
Arnatar Therapeutics, Inc |
Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
|
|
US12553050B2
(en)
|
2024-03-22 |
2026-02-17 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression
|
|
WO2026041784A1
(en)
|
2024-08-23 |
2026-02-26 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
|
WO2026054553A1
(ko)
*
|
2024-09-06 |
2026-03-12 |
올릭스 주식회사 |
선천성 면역 반응 기반 항암 요법을 위한 이중 가닥 rna 및 이의 용도
|
|
WO2026052079A1
(zh)
*
|
2024-09-07 |
2026-03-12 |
苏州瑞博生物技术股份有限公司 |
寡核苷酸、寡核苷酸缀合物及组合物和用途
|
|
WO2026052078A1
(zh)
*
|
2024-09-07 |
2026-03-12 |
苏州瑞博生物技术股份有限公司 |
寡核苷酸、寡核苷酸缀合物及组合物和用途
|